A robust platform for high-throughput screening of therapeutic strategies for acute and chronic spinal cord injury

• Main Authors: Vaibhav Patil, Enda O'Connell, Leo R. Quinlan, Howard Fearnhead, Siobhan McMahon, Abhay Pandit
• Format: Article
• Language: English
• Published: Elsevier 2021-03-01
• Series: iScience
• Subjects: Molecular Neuroscience; Cellular Neuroscience; Immunology; Proteomics
• Online Access: http://www.sciencedirect.com/science/article/pii/S2589004221001504

Summary: Astrocytes and microglia are critical regulators of inflammatory cascade after spinal cord injury (SCI). Existing glial in vitro studies do not replicate inflammatory phases associated with SCI. Here, we report an in vitro model of mixed glial culture where inflammation is induced by the administration of pro-inflammatory cytokines (tumor necrosis factor-α, interleukin-1β, and interleukin-6) to promote pathologically relevant “acute” and “chronic” inflammatory phases. We observed SCI relevant differential modulation of inflammatory pathways, cytokines, chemokines, and growth factors over 21 days. Mitochondrial dysfunction was associated with a cytokine combination treatment. Highly expressed cytokine induced neutrophil chemoattractant (CINC-3) chemokine was used as a biomarker to establish an enzyme-linked immunosorbent assay-based high-throughput screening (HTS) platform. We screened a 786-compound drug library to demonstrate the efficacy of the HTS platform. The developed model is robust and will facilitate in vitro screening of anti-reactive glial therapeutics for the treatment of SCI.